Citadel Advisors
CRNX

Citadel Advisors’s Crinetics Pharmaceuticals CRNX Stock Holding History

Citadel Advisors’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.18M Sell
138,329
-179,605
-56% -$6.68M ﹤0.01% 4657
2026
Q1 		$11.5M Buy
317,934
+63,214
+25% +$2.82M ﹤0.01% 3055
2025
Q4 		$11.9M Sell
254,720
-629,787
-71% -$28M ﹤0.01% 3036
2025
Q3 		$36.8M Buy
884,507
+230,872
+35% +$7.38M 0.01% 1679
2025
Q2 		$18.8M Buy
653,635
+615,084
+1,596% +$19M ﹤0.01% 2221
2025
Q1 		$1.29M Buy
38,551
+33,829
+716% +$1.26M ﹤0.01% 6380
2024
Q4 		$241K Sell
4,722
-130,412
-97% -$7.3M ﹤0.01% 10100
2024
Q3 		$6.91M Buy
135,134
+13,255
+11% +$684K ﹤0.01% 3441
2024
Q2 		$5.46M Sell
121,879
-49,545
-29% -$2.29M ﹤0.01% 3609
2024
Q1 		$8.02M Buy
171,424
+148,632
+652% +$5.82M ﹤0.01% 3235
2023
Q4 		$811K Sell
22,792
-136,444
-86% -$4.18M ﹤0.01% 7109
2023
Q3 		$4.74M Sell
159,236
-82,492
-34% -$1.7M ﹤0.01% 3735
2023
Q2 		$4.36M Sell
241,728
-43,867
-15% -$875K ﹤0.01% 3854
2023
Q1 		$4.59M Buy
285,595
+248,239
+665% +$4.59M ﹤0.01% 3960
2022
Q4 		$684K Sell
37,356
-2,855
-7% -$50.3K ﹤0.01% 7589
2022
Q3 		$790K Buy
+40,211
New +$820K ﹤0.01% 7493
2022
Q2 		– Sell
-49,839
Closed -$995K – 13013
2022
Q1 		$1.09M Sell
49,839
-14,985
-23% -$303K ﹤0.01% 7493
2021
Q4 		$1.84M Buy
64,824
+27,605
+74% +$681K ﹤0.01% 6437
2021
Q3 		$783K Sell
37,219
-23,439
-39% -$490K ﹤0.01% 8761
2021
Q2 		$1.14M Buy
+60,658
New +$1.07M ﹤0.01% 8007
2021
Q1 		– Sell
-46,864
Closed -$661K – 13218
2020
Q4 		$661K Buy
46,864
+7,762
+20% +$108K ﹤0.01% 7611
2020
Q3 		$613K Buy
39,102
+6,076
+18% +$92.9K ﹤0.01% 6924
2020
Q2 		$579K Sell
33,026
-2,711
-8% -$46.2K ﹤0.01% 6809
2020
Q1 		$526K Buy
35,737
+7,809
+28% +$160K ﹤0.01% 6383
2019
Q4 		$701K Buy
27,928
+295
+1% +$5.62K ﹤0.01% 6234
2019
Q3 		$416K Buy
27,633
+15,839
+134% +$308K ﹤0.01% 7067
2019
Q2 		$295K Buy
+11,794
New +$292K ﹤0.01% 7609

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors's CRNX Position: Q2 2026 in Review

Citadel Advisors reduced its Crinetics Pharmaceuticals (CRNX) stake by 56% in Q2 2026, selling an estimated $6.68M and leaving 138,329 shares worth $5.18M. The position accounts for ﹤0.01% of the portfolio, ranked #4657.

Citadel Advisors first reported a position in CRNX in Q2 2019 and has held it in 27 quarters since. The position peaked at $36.8M in Q3 2025. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • Citadel Advisors held 138,329 shares of Crinetics Pharmaceuticals worth $5.18M as of Q2 2026.
  • Citadel Advisors sold 179,605 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $6.68M.
  • Crinetics Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #4657 holding.
  • Citadel Advisors first reported a position in Crinetics Pharmaceuticals in Q2 2019 and has held it in 27 quarters since.
  • Citadel Advisors's Crinetics Pharmaceuticals position peaked at $36.8M in Q3 2025.
  • 267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.